+43.5%
UNP vs MRNA
+169.3%
-125.7%
-17.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | -3.9% | +1.7% | -2.1% |
| 7D | -1.2% | -17.6% | +16.4% | -0.9% |
| 30D | +2.8% | -5.1% | +7.9% | +2.8% |
| 3M | -0.5% | +220.8% | -221.3% | -4.5% |
| 6M | +10.9% | +321.7% | -310.8% | +3.9% |
| YTD | +30.4% | +601.3% | -570.9% | +16.1% |
| 1Y | +37.2% | +735.2% | -698.0% | +20.0% |
| All | +43.5% | +169.3% | -125.7% | +26.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling